Vascular Therapies announced today that a Phase 3 clinical trial of its Sirogen sirolimus formulation showed encouraging outcomes. Cresskill, N.J.-based Vascular Therapies designed its Sirogen proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. The Phase 3 clinical trial evaluated Sirogen in elderly end-stage renal disease patients, according to […]
Vascular Therapies closes $17.3m financing
Vascular Therapies announced that it closed an upsized private funding round worth more than $17 million with contributions from new and existing investors. The Cresskill, N.J.–based clinical-stage biopharma company originally targeted $15 million for the financing, but finished with a total of $17.3 million raised. Get the full story at our sister site, MassDevice.
Vascular Therapies raises $12m for drug-eluting vascular access implant
Vascular Therapies has raised $12.4 million from 29 investors as part of a $21.1 million round, according to a document filed last week with the SEC. The Cresskill, N.J.-based company is developing a sirolimus-eluting collagen implant for patients with end-stage renal disease. The bioresorbable drug-delivery system is designed to keep open a portal of entry […]